Cancer Care Centre, St George Hospital, Kogarah, NSW 2217, Australia; St George and Sutherland Clinical School, Faculty of Medicine, UNSW, Kensington, NSW 2052, Australia.
Department of Urology, St George Hospital, Kogarah, NSW 2217, Australia.
Cancer Lett. 2015 Dec 28;369(2):289-97. doi: 10.1016/j.canlet.2015.09.013. Epub 2015 Sep 30.
Radiotherapy (RT) is one of the most important strategies in cancer treatment. Radioresistance is a major challenge to RT and results in locoregional recurrence and metastasis. Thus, there is a great interest in investigating biomarkers to distinguish radiosensitive from radioresistant (RR) cancer patients. The development of proteomic techniques has sparked new searches for novel proteins for cancer biomarker discovery. Modern proteomic techniques allow for a high-throughput analysis of samples with the visualization and quantification of thousands of potential protein and peptide markers. The discovery of RR biomarkers can provide a clue for predicting RT response and discover therapeutic targets for developing personalised medicine of individual patients. In the past decade, emerging advanced proteomic technologies have been performed to identify radiation-related biomarkers in human cancers. This review discusses the mass spectrometry (MS)-based proteomic techniques in RR cancer biomarker discovery, summarises RR biomarkers identified in cancers from proteomics-based findings and explores potential values of RR biomarkers for future clinical trials.
放射治疗（RT）是癌症治疗中最重要的策略之一。放射抵抗是 RT 的主要挑战，导致局部区域复发和转移。因此，人们非常关注研究生物标志物，以区分敏感和抵抗（RR）的癌症患者。蛋白质组学技术的发展激发了对新的癌症生物标志物发现的探索。现代蛋白质组学技术允许对样品进行高通量分析，可视化和定量数千种潜在的蛋白质和肽标记物。RR 生物标志物的发现可以为预测 RT 反应提供线索，并为开发针对个体患者的个体化医学治疗靶点提供线索。在过去的十年中，已经开展了新兴的先进蛋白质组学技术，以鉴定人类癌症中的放射相关生物标志物。本文讨论了 RR 癌症生物标志物发现中的基于质谱（MS）的蛋白质组学技术，总结了基于蛋白质组学发现的癌症中的 RR 生物标志物，并探讨了 RR 生物标志物在未来临床试验中的潜在价值。
